MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Potential BlockBuster Technology and/or Business Model
Architects: Diagnostics_Liquid Biopsy
Cardiff Oncology, Inc. (Nasdaq: CRDF), Formerly Trovagene*
Organization & Developments: Cardiff Oncology
Parents
Cardiff Oncology, Inc. (Nasdaq: CRDF), Formerly Trovagene*
Children
*Cardiff Oncology is a clinical-stage company with the singular mission of developing new treatment options for cancer patients.
*Its lead drug candidate onvansertib, is a polo-like kinase 1 (PLK1) adenosine triphosphate (ATP) competitive inhibitor with the combination of chemotherapy and targeted therapeutics
*TrovaGene, Inc. (TROV), formerly, Xenomics
2020: Biotech Analysis Central Preview Series: Cardiff Oncology
2020: Cardiff Oncology's Onvansertib Could Possibly End Up Being A Solid Cancer Drug
2020: Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
2021: Cardiff Oncology: A High Risk-Reward Opportunity In KRAS-Mutated Cancers
2021: Our First Look At Cardiff Oncology
2022: Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment_seekingalpha.com
2022: Cardiff Oncology: Staying The Cours_ seekingalpha.com
2024: Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
2024: Cardiff Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer
2024: Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
2024: Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next_seekingalpha.com
2024: Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
2024: Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
2024: Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point
2024: Companies Like Cardiff Oncology (NASDAQ:CRDF) Are In A Position To Invest In Growth
2024: Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going
2025: Cardiff Oncology: Buying The First-Line Onvansertib Strategy
2025: Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity
2025: Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib
Jumps
*Key People: Cardiff Oncology
Finance & Acquisitions: Cardiff Oncology